Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer

Summary

This is a prospective, multicenter, randomized, open-label clinical trial. It aims to investigate whether intensive transarterial infusion chemotherapy (TAIC) followed by sequential intravenous chemotherapy (IVC) is clinically more effective than IVC alone in the treatment of unresectable colorectal cancer (uCRC).

Conditions

• Unresectable Colorectal Cancer

Interventions

PROCEDURE

Transarterial infusion chemotherapy (TAIC)

TAIC can increase the local intra-tumoral concentrations of chemotherapeutic agents by intensifying drug delivery into the tumor via super-selective catheterization of the tumor-feeding artery, and meanwhile reduce systematic toxicity.

PROCEDURE

Intravenous Chemotherapy（IVC）

Intravenous administration of chemotherapeutic agents is the mainstay of chemotherapy.

Sponsors & Collaborators

• Liaoning Cancer Hospital & Institute

  collaborator OTHER

• The Rocket Force Characteristic Medical Center

  collaborator UNKNOWN

• Second Affiliated Hospital of Nanchang University

  collaborator OTHER

• Affiliated Hospital of Hebei University

  collaborator OTHER

• The First Hospital of Qinhuangdao

  collaborator OTHER_GOV

• The Central Hospital of Handan City

  collaborator UNKNOWN

• The First People's Hospital of Jiujiang City

  collaborator UNKNOWN

• Changzhi Medical College

  collaborator OTHER

• Zibo Boshan District Traditional Chinese Medicine Hospital

  collaborator UNKNOWN

• Hebei Yixian Hospital

  collaborator UNKNOWN

• Baoding Mancheng District People's Hospital

  collaborator UNKNOWN

• The Shanghai Yangpu Central Hospital

  collaborator UNKNOWN

• Quanda Liu

  lead OTHER

Principal Investigators

• Quanda Liu, MD · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-03-20

Primary Completion

2027-12-31

Completion

2027-12-31

Countries

• China